![]() |
Volumn 102, Issue 4, 2017, Pages 578-580
|
Utilizing PBPK Modeling to Evaluate the Potential of a Significant Drug–Drug Interaction Between Clopidogrel and Dasabuvir: A Scientific Perspective
|
Author keywords
[No Author keywords available]
|
Indexed keywords
CLOPIDOGREL;
CYTOCHROME P450 2C8;
CYTOCHROME P450 3A4;
DASABUVIR;
DASABUVIR PLUS OMBITASVIR PLUS PARITAPREVIR PLUS RITONAVIR;
GEMFIBROZIL;
REPAGLINIDE;
SOLUTE CARRIER ORGANIC ANION TRANSPORTER 1B1;
ABT-333;
ANTIVIRUS AGENT;
DRUG COMBINATION;
GLUCURONIDE;
MACROCYCLIC COMPOUND;
RITONAVIR;
SULFONAMIDE;
TICLOPIDINE;
URACIL;
DRUG DISPOSITION;
DRUG EXPOSURE;
FOOD AND DRUG ADMINISTRATION;
HUMAN;
LOADING DRUG DOSE;
MEDICAL LITERATURE;
MULTIPLE DRUG DOSE;
NOTE;
PRESCRIPTION;
PRIORITY JOURNAL;
SINGLE DRUG DOSE;
ANALOGS AND DERIVATIVES;
BIOLOGICAL MODEL;
DRUG COMBINATION;
DRUG EFFECTS;
DRUG INTERACTION;
METABOLISM;
ANTIVIRAL AGENTS;
CYTOCHROME P-450 CYP2C8;
DRUG COMBINATIONS;
DRUG INTERACTIONS;
GLUCURONIDES;
HUMANS;
MACROCYCLIC COMPOUNDS;
MODELS, BIOLOGICAL;
RITONAVIR;
SULFONAMIDES;
TICLOPIDINE;
URACIL;
|
EID: 85018256225
PISSN: 00099236
EISSN: 15326535
Source Type: Journal
DOI: 10.1002/cpt.699 Document Type: Note |
Times cited : (11)
|
References (10)
|